NCT07154537View on ClinicalTrials.gov

Pneumococcal Conjugated Vaccine 13 (PCV13) for Patients With Multiple Myeloma (MM)

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

March 23, 2016

Primary Completion Date

April 3, 2024

Study Completion Date

July 31, 2027

Conditions
Multiple Myeloma
Interventions
BIOLOGICAL

2-dose PCV13

2 doses PCV13 with one month apart

BIOLOGICAL

1-dose PCV13

1 dose PCV13

Trial Locations (1)

100226

National Taiwan University Hospital, Taipei

All Listed Sponsors
collaborator

Ministry of Health and Welfare, Taiwan

OTHER_GOV

lead

National Taiwan University Hospital

OTHER